| Korea | Russia | Malaysia
Indonesia | All Others

eg.stem cell, stem cell treatment
Stem cell treatment | Parkinson's Disease | Multiple Sclerosis | ALS | Brain Injury | Spinal Cord Injury | Cerebaral Palsy | Batten Disease | Stroke
MSA | Muscular Dystrophy | Epilepsy | Optic neuritis | Encephalomyelitis | SMA | Huntingdon's disease | Friedrich ataxia | Diabetes
HOME > News > Article Content

Reduces Disability in Premature Babies With Serious Brain Hemorrhage


http://www.sciencedaily.com/releases/2010/03/100307215540.htm

ScienceDaily (Mar. 8, 2010)

The research, led by Andrew Whitelaw, Professor of Neonatal Medicine at the University of Bristol, and Ian Pople, paediatric neurosurgeon at North Bristol NHS Trust, has shown that, after a haemorrhage, the fluid inside the ventricles contains substances potentially toxic to the immature brain.

In 1998, Professor Whitelaw and Ian Pople pioneered a technique by which the inside of the brain was "washed out" to remove the toxic substances.

The Bristol team report on this pioneering work in an article published online in Pediatrics, the journal of the American Academy of Pediatrics.

One of the most feared complications of being born very early is bleeding into the ventricles in the centre of the brain. A large haemorrhage usually injures the developing brain with consequent cerebral palsy and serious learning difficulties in several hundred children each year in the UK. In about half of the children, fluid builds up inside the brain causing the brain and head to expand excessively. This condition is called 'hydrocephalus'.

Until now, no treatment in these premature babies has been shown to reduce disability, or improve any aspect of health. The standard approach has been to repeatedly insert needles into the spine or head to remove fluid until, after several months, a permanent surgical "shunt" drains fluid from the brain to the abdomen.

Professor Whitelaw said: "Premature babies are particularly at risk of bleeding because in the middle of pregnancy, the fetus has many fragile blood vessels in the centre of the brain. These blood vessels shrink by full term and bleeding is rare in babies born at 40 weeks."

Professor Whitelaw and Ian Pople have researched the mechanisms and treatment of the condition called 'hydrocephalus' over the last 20 years.

If a premature baby was shown by repeated ultrasound scans to have had a large haemorrhage and then expanded ventricles, the baby was anaesthetised and two tubes were inserted into the ventricles in the brain. One tube was used to continuously drain out the cola-coloured fluid while the other tube was used to let clear fluid flow in. The pressure in the brain was measured continuously and more fluid was drained out than flowed in so the brain slowly decompressed. When the fluid draining out cleared, the two tubes were removed. This took on average three days. After four years work on the feasibility and practicality of the technique, a randomised trial, funded by grants from Cerebra and the James and Grace Anderson Trust, was started.

From 2003 to 2006, 77 premature babies with large brain haemorrhages in Bristol, Glasgow, Katowice (Poland) and Bergen (Norway) were recruited. Thirty-nine babies had the ventricles washed out using the Drainage, Irrigation and Fibrinolytic Therapy (DRIFT) and 38 had standard treatment.

When they were two years old, independent assessors examined all the survivors. Of 39 infants assigned to being washed out, 21 (54 per cent) died or were severely disabled versus 27 of 38 (71 per cent) in the standard group. Amongst the survivors, 11 of 35 (31 per cent) in the DRIFT group had severe cognitive disability versus 19 of 32 (59 percent) in the standard group. Median Mental Development Index was 68 (out of 100) in the washout group, and below 50 with standard care. These results are statistically and clinically significant.

Ian Pople said: "This is the first time that any treatment anywhere in the world has been shown to benefit these very vulnerable babies. Initially known as "Drainage, Irrigation and Fibrinolytic Therapy (DRIFT)" this treatment is now called "ventricular lavage" and it is hoped that in the very near future it will be set up as a service at Southmead Hospital in Bristol."

The patient, Isaac Walker-Cox

Isaac Walker-Cox was one of the first babies to have the pioneering 'brain-washing' treatment following a brain haemorrhage after being born 13 weeks early at Southmead Hospital in Bristol.

He is now a happy nine-year-old who loves school and playing on his computer but in 2000 his parents Rebekah and Steven Walker-Cox, from Yate, South Gloucestershire, made the brave decision to allow doctors to carry out the revolutionary treatment on their fragile son to wash out toxic fluids that were inflating his brain.

At that time Isaac was one of only a handful of babies who had had the Drainage, Irrigation and Fibrinolytic Therapy (DRIFT) pioneered by Andrew Whitelaw, Professor of Neonatal Medicine at the University of Bristol, and Ian Pople, paediatric neurosurgeon at North Bristol NHS Trust.

Isaac was born 13 weeks early weighing just 2lbs and 10oz at Southmead Hospital and at just 48 hours old he had a haemorrhage on the right side of his brain.

The ventricles in Isaac's brain were filling with cerebrospinal fluid (CSF) and blood causing 'hydrocephalus', where a build-up of fluid puts pressure on the brain.


The standard treatment for the majority of patients with 'hydrocephalus' after a haemorrhage is to have needles inserted repeatedly into the spine or head to drain fluid and, after two to three months to have a shunt inserted permanently connecting the brain to the abdomen. But this treatment has risks including infection and sudden blockage.

Professor Whitelaw and Mr Pople's long-term study published online in Pediatrics, the journal of the American Academy of Pediatrics, has shown that babies who have had DRIFT instead of standard treatment go on to have less developmental problems into childhood.


The study showed that at two years old children who had had DRIFT after a brain haemorrhage when they were babies were less likely to have severe cognitive disability and their mental development was higher than in children who had standard treatment.


Isaac had the DRIFT procedure when he was just two weeks old and was attached to a machine for four days to pump out the fluid.

Mrs Walker-Cox, 36, said: "We were told after the haemorrhage that Isaac may not make it through the night, that he had one per cent survival rate.

"When Professor Whitelaw told us about the research trial, we thought we didn't have anything to lose.

"Professor Whitelaw had so far carried it out on 17 babies so it was very new but we decided that if it worked it would mean Isaac did not have to have a shunt.

"We just kept watching the liquid go through the pump day after day, just waiting to see if it worked."

Isaac now has mild paralysis on the left side of his body caused by the haemorrhage but he doesn't let it hold him back.

Mrs Walker-Cox said: "We were told Isaac may not be able to walk, and we didn't think he would be able to go to a mainstream school because we expected he would have a learning disability.

"But mentally he has no problems at all, he has an above average reading age and he is very good with computers.

"He just gets on with life and is an outgoing, happy little boy.

"We are really excited to have been part of the DRIFT treatment in the early days, it's nice for Isaac too because he knows what he has been through and he feels proud."


Professor Andrew Whitelaw, a Neonatologist and Ian Pople, Paediatric Neurosurgeon at North Bristol NHS Trust, have pioneered DRIFT at the University of Bristol and it is hoped it will soon be offered, renamed 'ventricular lavage', as a service at Southmead Hospital in Bristol.

Isaac Walk-Cox lives in Yate, South Gloucestershire, with mum Rebekah, 36, dad Steven, 35, and brothers Owen, six, and Ethan, three.



Related Information:

  • The Washington Post report regarding our center and specialized stem cell treatment   
  • Stem cell therapy, a promising novel endeavor for neurological disorders   
  • Major ALS breakthrough-common cause of all forms of ALS discovered   
  • Imaging Study Shows Slower Growth In Autistic Brains Extending Into Adolescence   
  • 'Pushing Limits' - New Drug Strategies For Alzheimer's, Multiple Sclerosis   
  • Study Suggests Varying Practice Sessions May Benefit People With Motor Disorders   
  • New Drug Strategies for Alzheimer's and Multiple Sclerosis   
  • Antiviral Drugs May Slow Alzheimer's Progression   
  • Precision With Stem Cells a Step Forward for Treating Multiple Sclerosis, Other Diseases   
  • Minority Children Less Likely to Receive CT Scans Following Head Trauma   
  • Reassurance for Dementia Sufferers On Impact of Common Drugs   
  • Understanding the Beginnings of Embryonic Stem Cells Helps Predict the Future   
  • By Reprogramming Skin Cells Into Brain Cells, Scientists Gain New Insights Into Mental Disorders   
  • Family History May Have More Important Role Than Previously Thought in Development of Alzheimer Disease   
  • Evidence Points to Potential Roles for Cognitive Rehabilitation Therapy in Treating Traumatic Brain Injury,   
  • New Drug Target for Alzheimer's, Stroke Discovered   
  • New Drug Target for Alzheimer's, Stroke Discovered   
  • A Safe Vaccination for Alzheimer's Disease?   
  • Think You're in Poor Health? It Could Increase Your Odds of Dementia   
  • Models of Autism Show That Gene Copy Number Controls Brain Structure and Behavior   
  • Patient-Specific Stem Cells: Major Step Toward Cell-Based Therapies for Life-Threatening Diseases   
  • One Quarter of Seniors Over 70 Have Had Silent Strokes   
  • Remitting Multiple Sclerosis: Natalizumab Reduces Relapses and Disability   
  • Seeds of Destruction in Parkinson's Disease: Spread of Diseased Proteins Kills Neurons   
  • Even High-But-Normal Blood Pressure Elevates Stroke Risk   
  • Commonly Used Supplement May Improve Recovery from Spinal Cord Injuries   
  • Key to Survival of Brain Cells Discovered   
  • Correcting Sickle Cell Disease With Stem Cells   
  • New Stem Cell Activity Identified in Human Brain   
  • New Stem Cell Activity Identified in Human Brain   
  • Treatment
    The Parkinson's Clinical Center
    Doctor Blogs
    Treatment Data
    Contact Us

  • What are stem cells and how do they work to treat various diseases?   
  • How do stem cells know where to go and what to do?   
  • What kinds of stem cells does your medical center use and are they safe?   
  • Where do the stem cells come from?   
  • Is stem cell treatment safe? Is it really effective?   
  • How do I know if I am a good candidate for stem cell therapy?   
  • How long should I expect to stay in Beijing for the treatment?   
  • Can you use adult stem cells from my own bone marrow?   
  • What methods do you use to transplant stem cells into the patient's body?   
  • What should I expect to experience during the stem cell treatment?   
  • Do the doctors use anesthesia during the operation?   
  • What other drugs does the doctor combine with the stem cells for therapy?   
  • How long after surgery will it be before I can bathe or shower?   
  • For Batten disease treatment, what type of stem cells are used?   
  • About the neural growth factors that your medical center use   
  • If your hospitals have an age restriction on patients?   
  • What medications do you use on Batten disease patients?   
  • Is it possible for you to manufacture the TPP1 enzyme and deliver it?   
  • When I send my records to your hospital, does a doctor read them?   
  • Is general anesthesia used?   
  • Is other therapy done in addition to stem cell infusion?   
  • What types of rehabilitation training is done?   
  • What will my treatment schedule be like?   
  • Does the doctor have to penetrate the spinal canal to infuse the stem cells   
  • If I have to have surgery, how long will it take for the wound to heal?   
  • Will I lose very much blood?   
  • If there is surgery, can I fly back home before the wound has healed?   
  • Does your medical center also offer conventional treatment?   
  • What is the most effective way to contact us?   
  • Are stem cells pre-tested for HIV and Hepatitis? What else do you test?   
  • Send Inquiry Contact Us Sitemap Help

    Link:Like Cell Research Center | stemcellshezhong.com
    Copyright © 2011 unistemcells.com All rights reserved.